231 related articles for article (PubMed ID: 28039264)
1. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
[No Abstract] [Full Text] [Related]
2. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
[TBL] [Abstract][Full Text] [Related]
4. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.
Li S; Wei Q; Li Q; Zhang B; Xiao Q
Cancer Biol Ther; 2015; 16(6):866-75. PubMed ID: 25920936
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
[TBL] [Abstract][Full Text] [Related]
6. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
7. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.
Tanaka T; Ikegami Y; Nakazawa H; Kuriyama N; Oki M; Hanai J; Sukhatme VP; Kaneki M
J Cell Physiol; 2017 Jan; 232(1):192-201. PubMed ID: 27137755
[TBL] [Abstract][Full Text] [Related]
9. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
[TBL] [Abstract][Full Text] [Related]
10. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.
Liao D; Corle C; Seagroves TN; Johnson RS
Cancer Res; 2007 Jan; 67(2):563-72. PubMed ID: 17234764
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.
Moschetta MG; Maschio LB; Jardim-Perassi BV; Gelaleti GB; Lopes JR; Leonel C; Gonçalves Ndo N; Ferreira LC; Martins GR; Borin TF; Zuccari DA
Oncol Rep; 2015 May; 33(5):2345-53. PubMed ID: 25779537
[TBL] [Abstract][Full Text] [Related]
14. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model.
Kim DH; Sung B; Kim JA; Kang YJ; Hwang SY; Hwang NL; Suh H; Choi YH; Im E; Chung HY; Kim ND
Int J Oncol; 2017 Aug; 51(2):715-723. PubMed ID: 28656256
[TBL] [Abstract][Full Text] [Related]
15. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
Park JM; Terabe M; Sakai Y; Munasinghe J; Forni G; Morris JC; Berzofsky JA
J Immunol; 2005 Apr; 174(7):4228-36. PubMed ID: 15778385
[TBL] [Abstract][Full Text] [Related]
16. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
17. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
[TBL] [Abstract][Full Text] [Related]
18. LncRNA LINC00649 promotes the growth and metastasis of triple-negative breast cancer by maintaining the stability of HIF-1α through the NF90/NF45 complex.
Zhang J; Du C; Zhang L; Wang Y; Zhang Y; Li J
Cell Cycle; 2022 May; 21(10):1034-1047. PubMed ID: 35188449
[TBL] [Abstract][Full Text] [Related]
19. Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
Mahdevar E; Kefayat A; Safavi A; Behnia A; Hejazi SH; Javid A; Ghahremani F
Sci Rep; 2021 Nov; 11(1):23121. PubMed ID: 34848739
[TBL] [Abstract][Full Text] [Related]
20. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance.
Whelan KA; Schwab LP; Karakashev SV; Franchetti L; Johannes GJ; Seagroves TN; Reginato MJ
J Biol Chem; 2013 May; 288(22):15865-77. PubMed ID: 23585570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
